Bioinformatics Institute of India: Pharma Department

SIRO forms alliance with Korean CRO DreamCIS

SIRO Clinpharm, a contract research organization (CRO) with presence in India, Western and Central Eastern Europe, and the US has announced its alliance with DreamCIS, a leading CRO based in Seoul, South Korea.

DreamCIS has experience in offering clinical research services to pharmaceutical companies, bio venture companies, medical device manufacturers, and functional food producers. Their services range includes clinical trial management, pharmacovigilance, post marketing surveillance (PMS), data management, biostatistics and quality assurance services.

“This pact will help us to build a strong competitive advantage in the Asia Pacific region, while on the other hand it will create a sustainable value for our existing as well as potential customers,” said Mr Ajit Nair, President, SIRO Clinpharm, India. He further added that, “Our goal is to offer a wider platform of patient recruitment capabilities from Asia Pacific region for our global client base.”

“We are one of the leading and fast growing CROs in South Korea. However, looking at the increasing number of global clinical trials and the rapid growth in Asian clinical trials market, we were looking at associating ourselves with a CRO having a global exposure; not only from business vertical perspective but also from perspective of moving up on the learning curve. I think our mutually beneficial alliance with SIRO is a definite step in this direction,” said Mr Won-Jung Choi, President, DreamCIS.

“Korea is a rapidly growing clinical trials market due to various advantages it offers pre-approved and well-equipped clinical trial sites, trained professionals, and transparent and efficient regulatory processes. We are confident this alliance will be of immense value addition to SIRO and widen our global service capabilities," said Mr Chetan Tamhankar, Chief Executive Officer, SIRO Clinpharm.